Bluebird Bio has one program (for ALD) which as has just passed the Pl/ll clinical trial stage and their MC is ~$A700M.
Xmas 2015 would be the conclusion of our Pl/ll trial for HCV so maybe Bluebird is a guide to where we could be. (I know that HCV market is much larger than that of ALD but what matters as far as our MC is concerned is the market share that investors/big pharma think TT-034 will get.)
Gradalis could go public before then and I wonder what their IPO would be worth?
Add to My Watchlist
What is My Watchlist?